drugset / Trial / NCT00694044

Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects

NCT00694044

Phase 1 Completed 50 enrolled Pfizer
RandomizedParallel-groupDouble-blind

Summary

1. Characterize the tolerability and safety of repeated doses of varenicline in healthy non-smoking elderly subjects. 2. Describe the steady state pharmacokinetics of varenicline in healthy non-smoking elderly subjects. 3. Evaluate the potential effects of repeat doses of varenicline on cognition in healtly non-smoking elderly subjects.

Timeline

Start
2008-04
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Varenicline Small molecule 0.5 mg
Comparator Varenicline Small molecule 1 mg

Indications

No indication recorded.